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Cytochrome P450 oxidoreductase (POR) supports reactions of microsomal cytochrome
P450 which metabolize drugs and steroid hormones. Mutations in POR cause disorders
of sexual development. P450 oxidoreductase deficiency (PORD) was initially identified in
patients with Antley–Bixler syndrome (ABS) but now it has been established as a separate
disorder of sexual development (DSD). Here we are summarizing the work on variations in
POR related to metabolism of drugs and xenobiotics. We have compiled mutation data on
reported cases of PORD from clinical studies. Mutations found in patients with defective
steroid profiles impact metabolism of steroid hormones as well as drugs. Some trends are
emerging that establish certain founder mutations in distinct populations, with Japanese
(R457H), Caucasian (A287P), and Turkish (399–401) populations showing repeated findings
of similar mutations. Most other mutations are found as single occurrences. A large
number of different variants in POR gene with more than 130 amino acid changes are
now listed in databases. Among the polymorphisms, the A503V is found in about 30% of
all alleles but there are some differences across different population groups.
Keywords: P450 oxidoreductase, P450 oxidoreductase deficiency, Antley–Bixler syndrome, steroid metabolism,
disorders of sexual development, drug metabolism, P450c17, aromatase
INTRODUCTION
Cytochrome P450 reductase (POR) has a major role in
metabolism of drugs and steroids (Flück et al., 2007; Pandey
and Flück, 2013; Riddick et al., 2013) (Figure 1). All micro-
somal cytochrome P450 get electrons from nicotinamide ade-
nine dinucleotide phosphate (NADPH) through POR (Zanger
and Schwab, 2013) (Figure 2). A single gene of 71,754 bp
located on chromosome 7 (locus 7q11.23) encodes human
POR (Table 1). The human POR gene has one non-coding
exon and 15 protein-coding exons and encodes a 680 amino
acid membrane bound protein (RefSeq protein: NP_000932,
UniProt P16435). Disruption of POR affects all microsomal
P450 enzyme activities (Flück et al., 2007; Pandey and Flück,
2013). POR also supplies electrons to many other interac-
tion partners. POR knockout mice are embryonic lethal (Shen
et al., 2002; Otto et al., 2003). The liver-specific knockout of
POR produces mice with lower metabolism and lipid accumu-
lation (Gu et al., 2003; Henderson et al., 2003; Porter et al.,
2011).
Cytochrome P450 oxidoreductase deficiency (PORD);
(OMIM: 613571 and OMIM: 201750) is a form of congenital
adrenal hyperplasia (Flück et al., 2004; Miller et al., 2004; Pandey
et al., 2004; Flück and Pandey, 2013). Clinical symptoms of
PORD were described in a 46,XY patient with disorder of
sexual development (DSD) (Peterson et al., 1985). Sequencing
of the POR gene in a Japanese 46,XX girl with a metabolic
profile of steroid deficiency and symptoms of Antley–Bixler
Syndrome (ABS) led to the characterization of PORD (Flück
et al., 2004). Skeletal malformation in many ABS patients with
ambiguous genitalia and defective steroid metabolism have
now been linked to PORD (Huang et al., 2005). PORD is now
listed as a separate metabolic disorder (Huang et al., 2005). An
overview of reported cases shows that PORD disrupts steroid
biosynthesis in adrenal gland and gonads (Huang et al., 2005;
Dhir et al., 2007; Pandey et al., 2007; Flück et al., 2011a). This
often leads to genital ambiguity at birth in both male and
female. The absence of testosterone (T)/dihydrotestosterone
(DHT) leads to development of female external genitalia (Flück
and Pandey, in press). The presence of T/DHT triggers the
formation of male genitalia. In humans the testosterone is mainly
produced in testes by a process that starts by the conversion of
pregnenolone to 17-hydroxypregnenolone (17-OHPreg) and
dehydroepiandrosterone (DHEA) by the enzyme CYP17A1 in
the adrenal (Miller and Auchus, 2011) (Figure 3). Like other
microsomal P450 CYP17A1 requires POR (Miller and Auchus,
2011; Pandey and Flück, 2013). Aromatase converts androgens to
estrogens and also requires POR (Pandey et al., 2007; Flück et al.,
2011a; Bouchoucha et al., 2014). Thus, a defective POR affects
sexual development (Flück and Pandey, 2011; Fukami et al.,
2013) in both male and female. Many cases still do not have final
diagnosis and other genes may be involved (Flück and Pandey,
in press). Recently we have reported the first human mutations
in aldo-keto reductases AKR1C2 (OMIM: 614279) and AKR1C4
(OMIM: 600451) (Flück et al., 2011b). This established two
distinct pathways for the biosynthesis of androgens in fetal
testis for control of sexual differentiation between male and
female (Flück et al., 2011b; Biason-Lauber et al., 2013a,b; Flück
and Pandey, in press). POR also plays a role in this alternate
pathway (Biason-Lauber et al., 2013a; Pandey and Flück, 2013)
(Figure 3). A large number of POR variants containing more
than 130 amino acid changes in the POR protein have now
been reported (Figure 4) by multiple researchers, and a list
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of variants in human POR is available at CYP allele website
(www.cypalleles.ki.se/por.htm) (Huang et al., 2008; Sim et al.,
2009; Flück et al., 2011a; Tomkova et al., 2012).
This review describes current status of information and
research on disease related as well as naturally occurring vari-
ants of the POR gene. We have collected data on reports of
PORD to summarize the current information on effects of POR
mutations on enzymatic activities of redox partners. In addi-
tion, we have compiled the list of naturally occurring variants
in POR gene that have been reported by researchers specifically
FIGURE 1 | Role of P450 oxidoreductase in biochemical pathways. POR
is required for multiple metabolic processes especially the microsomal
P450 enzymes involved in metabolism of xenobiotics.
sequencing the POR gene in distinct populations. We have also
included information on POR variants available in genomic
databases from large scale sequencing studies. Recently many
POR variants have been studied for effects on drug metabo-
lizing enzymes. We have also summarized studies describing
the impact of individual POR variants on in vitro as well as
in vivo drug metabolism cytochrome P450 activities. We have
labeled the POR variants found in patients with disorders of
steroid metabolism as “mutants” and variants identified from
normal human population as “polymorphisms” (Figure 4). List
of POR variants was compiled from publication of PORD case
reports, POR sequencing studies, and human genome sequenc-
ing projects available through NCBI databases (http://www.ncbi.
nlm.nih.gov).
POR AND STEROID METABOLISM
PORD was identified as a DSD resulting from disruption of
steroid metabolizing cytochrome P450 activities (Flück et al.,
2004; Pandey et al., 2004). After the identification of POR variants
in normal human population, early reports analyzed the impact
of POR variants on three microsomal cytochrome P450 involved
in steroid metabolism (CYP17A1, CYP19A1, and CYP21A2)
(Flück et al., 2004; Huang et al., 2005; Dhir et al., 2007; Pandey
et al., 2007). A large number of POR mutations or polymor-
phisms (Huang et al., 2005; Flück et al., 2011a) have been studied
and analyzed based on known structures of POR (Xia et al.,
2011; Pandey and Flück, 2013). Many mutations in POR found
in patients are in co-factor binding sites and cause severe POR
deficiency. The p.A115V variation first found in patients seems
to be a polymorphism (Huang et al., 2008) and shows similar
to wild type activity in CYP17A1 assays. The p.T142A mutation
FIGURE 2 | Electron transfer from NADPH to redox partners of
POR. NADPH binds to POR located into the endoplasmic reticulum,
and donates electrons which are received by FAD. Electron transfer
to FAD causes a conformational change that brings together the
FAD and FMN domains and electrons are transferred from FAD to
FMN. The FMN domain of POR interacts with the P450s and
other redox partners and completes the final step of electron
transfer.
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is close to FMN binding site but shows more than 50% of WT
activity (Huang et al., 2005). The mutation p.Q153R also near
the FMN binding site, had reduced POR activity in CYP17A1
assays (Table 2 and Figure 5) (Huang et al., 2005). An XY patient
of Canadian origin with symptoms of 17-, 21-hydroxylase had
POR mutation p.G188_V191dup but enzyme activity data are
not available (Krone et al., 2012). The mutation p.A287P is most
common in patients from Europe (Huang et al., 2005). It retains
20–40% of WT activity in CYP17A1 assays (Table 2) but had
no effect on either CYP19A1 (Flück et al., 2004; Huang et al.,
Table 1 | Database accession numbers for human POR.
RefSeq Protein NP_000932
RefSeq RNA NM_000941
UniGene Hs.354056
Uniprot P16435
GeneID 5447
GeneCards GC07P075528
Ensembl ENSG00000127948
HGNC HGNC:9208
2005; Pandey et al., 2007) or CYP21A2 activity (Dhir et al.,
2007). The polymorphism p.R316W shows normal activity in
most assays (Huang et al., 2005; Pandey and Flück, 2013). The
mutation p.P399_E401del found in two unrelated Turkish fami-
lies (Flück et al., 2011a) had 68–85% of WT activity in different
P450 assays (Flück et al., 2011a). Polymorphism p.G413S was
identified in a sequencing study by Bioventures Inc. (Solus et al.,
2004), retains wild type activity in many assays (Table 3) (Huang
et al., 2005). A DSD patient of Pakistani origin (17 and 21-
hydroxylase deficiencies) had p.R498P mutation (Krone et al.,
2012). No enzymatic data for p.R498P are available. The varia-
tions p.A503V and the p.G504R have>50% activity (Huang et al.,
2005). A link between p.A503V variant of POR and altered steroid
profile in normal population was not found (Utriainen et al.,
2012). The mutation p.G539R had <10% activity in the 17,20
lyase assay and 46% activity in the 17α-hydroxylase assay (Huang
et al., 2005). The mutation p.C569Y in human POR (Flück et al.,
2004) had 13% of 17,20 lyase activity and 28% of 17α-hydroxylase
activity (Huang et al., 2005). The polymorphism p.R600W has 7–
60% of WT activity in different assays (Huang et al., 2008). The
p.C569Y mutation was compound heterozygote together with
p.V608F (Flück et al., 2004). The p.V608F retained 57% of 17,20
FIGURE 3 | Role of POR in biosynthesis of androgens in classic and
alternate pathways. The classic pathway proceeds from transfer
cholesterol to mitochondrion through steroidogenic acute regulatory
protein (StAR). In the mitochondrion cholesterol is converted to
pregnenolone by CYP11A1. The biosynthesis process then continues from
pregnenolone to 17OHPreg and DHEA to androstenedione or
androstenediol and then to testosterone in testicular Leydig cells.
Testosterone (T) is converted to dihydrotesterone (DHT) in genital skin.
The backdoor pathway proceeds from 17OHPreg to 17OHProg, 17OH-DHP,
17OH-Allo, androsterone, androstanediol (A’diol) and then to DHT in the
testis. Abbreviations: CYP11A1, P450scc, cholesterol side-chain cleavage
enzyme; StAR, steroidogenic acute regulatory protein; FDX1,
Adrenodoxin; FDXR, NADPH adrenodoxin oxidoreductase; CYP17A1,
P450c17, 17α-hydroxylase/17,20-lyase; HSD3B2, 3βHSD2, 3β-hydroxysteroid
dehydrogenase, type 2; CYB5, cytochrome b5; POR, P450 oxidoreductase;
HSD17B3, 17βHSD3, 17β-hydroxysteroid dehydrogenase, type 3; and
SRD5A2, 5α-reductase, type 2. The alternative pathway has four additional
enzymes: SRD5A1, 5α-reductase, type 1; AKR1C2, Aldo-keto reductase
1C2, 3αHSD3; and AKR1C4, Aldo-keto reductase 1C4, 3αHSD1, for
reductive 3αHSD activity; and HSD17B6, 17βHSD6, 17β-hydroxysteroid
dehydrogenase, type 6; and/or AKR1C2/4 for oxidative 3αHSD activity.
Full steroid names: 17OHPreg, 17-hydroxypregnenolone; 17OHProg,
17-hydroxyprogesterone; 17OH-DHP, 17-hydroxydihydroprogesterone
(5α-pregnan-3α,17α-ol-20-one); 17OH-Allo, 17-hydroxyallopregnanolone
(5α-pregnan-3α,17α-diol-20-one; P’diol); A’diol, androstanediol; T,
testosterone; DHT, dihydrotestosterone, DHEA, dehydroepiandrosterone.
www.frontiersin.org May 2014 | Volume 5 | Article 103 | 3
Pandey and Sproll Human POR
FIGURE 4 | POR protein sequence showingmissensemutations identified
in patients and variations from normal human population.Mutation found
in patients are indicated with red triangle while variants identified from healthy
individuals are indicated with blue triangle. Amino acids are colored based on
chemical properties; acidic residues (D, E) are in red, basic residues (H, R, K)
are in blue, and rest of the polar amino acids (N, C, Q, S, T, and Y) are in green.
Data were compiled from information available in NCBI SNP database and
POR listing at CYPallele database (Sim et al., 2009) as of April 2014.
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Table 2 | Influence of POR variants found in patients with disorder of sexual development, on the enzyme activities of its redox partners.
POR DBSNP id CYP3A4 HO-1 Cyt c NADPH CYP17A1 CYP17A1 CYP19A1 CYP1A2 CYP2C19 CYP2D6
red Oxi 17OH-ase 17,20 lyase
WT – 100 100 100 100 100 100 100 100 100 100
p.T142A – 85 81 49 52 60 54 – 3 –
p.Q153R – 119 72 9 11 31 27 – 144 284 128
p.Y181D rs72552771 – – – – – – – –
p.N185K 6 1 – –
p.M263V – 76 57 9 13 92 136
p.A287P rs121912974 26 49 93 104 40 21 104 – – –
p.P339_E401del – 20 26 31 30
p.R457H rs28931608 – – 1 – 3 – 1 – – –
p.Y459H – – – – – 11 – – – –
p.V492E rs28931606 – – – – 3 – <1 – –
p.G539R rs121912976 9 – 46 8 10 33
p.L565P – 14 1 32 19 – –
p.C569Y rs28931607 32 33 18 7 28 13 51 6 –
p.L577R 5 4 46 27
p.Y607C rs72557954 – 20 76 40 7 24
p.V608F rs72552772 16 32 8 3 80 57 24 5 –
p.R616X – – – – 6 – – – – –
p.V631I rs145782750 89 96 74 23 51 40 – 6 23
p.delF646 – 88 95 36 94 97 46 – – –
Activities are shown as percentage of the wild-type POR. POR, P450 oxidoreductase. Data were compiled from previous studies (Flück et al., 2004, 2010, 2011a;
Pandey et al., 2004, 2007, 2010; Huang et al., 2005, 2008; Agrawal et al., 2008, 2010; Nicolo et al., 2010; Sandee et al., 2010). The V631I and Y607C were initially
found in patients but later studies established those as normal population variants. Mutations listed in bold abolish all activity. These were found in patients with
severe forms of disease and affected residues are located near co-factor binding sites of POR.
Enzymes/reactions and substrates (in parenthesis) listed in this table: CYP3A4: [BOMCC (7-Benzyloxy-4-trifluoromethylcoumarin)]; HO-1: Heme oxygenase-1 (heme);
Cyt c red: Cytochrome c reduction (cytochrome c); NADPH ox: NADPH oxidation (NADPH); CYP17A1 17OH-ase: (Progesterone); CYP17A1 17,20 Lyase: (17-hydroxy
Pregnenolone), CYP19A1: (androstenedione); CYP1A2, CYP2C19, and CYP2D6: [EOMCC (7-ethoxy-methyloxy-3-cyanocoumarin)].
lyase activity and 80% of 17α-hydroxylase activity (Table 2 and
Figure 5) (Huang et al., 2005; Pandey et al., 2007). Both p.C569Y
and p.V608F hadmore severe effects on CYP19A1 activity than on
CYP17A1 activities (Flück et al., 2004; Huang et al., 2005; Pandey
et al., 2007). The p.H628P affected both CYP17A1 and CYP21A2
activities to similar extent (Dhir et al., 2007). The p.Y607C had
greater effects on CYP17A1 and CYP19A1 activities but CYP21A2
activity was 80% of WT (Idkowiak et al., 2010). There were no
severe malformations in the p.Y607C patient (Huang et al., 2005;
Idkowiak et al., 2010). A normal steroid profile also suggests nor-
mal activities of steroidogenic enzymes in vivo (Idkowiak et al.,
2010). The p.V631I retained 40–50% of activity in the CYP17A1
assays. Deletion of F646 had no effect on 17α-hydroxylase activ-
ity but caused a 54% reduction in 17,20 lyase activity (Huang
et al., 2005). Other reported mutants in the region p.Y578C and
p.E580Q were not tested in enzymatic assays (Pandey and Flück,
2013).
POR AND DRUG METABOLISM
After the discovery of POR mutations in patients and identifica-
tion several variants of POR in healthy individuals we suggested
that POR variants may also impact drug metabolizing P450
enzymes since POR is necessary for activities of all microsomal
P450 (Flück et al., 2004, 2007; Pandey et al., 2004; Huang et al.,
2005). Variations in POR may affect many different redox part-
ners. Many recent studies reported effects of POR variants on
several drug metabolizing P450s (Agrawal et al., 2008, 2010; Hart
et al., 2008; Kranendonk et al., 2008; Gomes et al., 2009; Miller
et al., 2009; Oneda et al., 2009; Flück et al., 2010; Marohnic
et al., 2010; Nicolo et al., 2010; Tomalik-Scharte et al., 2010) and
other metabolic processes (Agrawal et al., 2010; Flück et al., 2010;
Marohnic et al., 2010; Nicolo et al., 2010; Pandey et al., 2010;
Sandee et al., 2010; Zhang et al., 2011). Here we are describing the
reports on human studies, an overview of metabolic activities in
POR mouse models by laboratories of Roland Wolf and Xin-Xin
Ding has been reviewed earlier (Riddick et al., 2013).
Cytochrome P450 3A4 (CYP3A4) metabolizes a wide range of
drugs and xenobiotics (Klein and Zanger, 2013;Meyer et al., 2013;
Zanger and Schwab, 2013). PORmutations affect CYP3A4 activi-
ties in vitro (Nicolo et al., 2010). The PORmutant p.A287P (com-
mon mutation found in patients from “European” population)
showed 75% loss of CYP3A4 activity (Table 2 and Figure 6)
(Flück et al., 2010; Nicolo et al., 2010). The p.R316W and
p.G413S variants had close to WT activities (Flück et al., 2010).
The mutations disrupting FAD binding (p.R457H, p.Y459H and
p.V492E) resulted in complete loss of CYP3A4 activity (Flück
et al., 2010). POR polymorphisms p.A503V and p.G504R showed
close to normal activities (Table 3) (Flück et al., 2010). POR
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FIGURE 5 | Impact of POR variants on CYP17A1 activity. A pie chart
showing the impact of POR variants on CYP17A1 17,20 lyase activity. The
variants which had <5% of WT activity are grouped as red, variants with
5–25% of WT activity are in orange, variants with 25–50% of activity are in
yellow, and variants with >50% activity are in green. A large number of
recently identified variants from large scale sequencing studies have not
been tested in enzymatic assays and these are grouped in gray color pie.
mutations p.C569Y and p.V608F resulted in 65–85% loss of
CYP3A4 and p.R616X lost all activity (Table 2) (Flück et al.,
2010). The POR mutant p.Y181D resulted in almost total loss
of CYP3A4 activity, while variant p.Q153R was normal and vari-
ant p.T142A had 75–80% activity (Flück et al., 2010). A larger
study of POR variants with CYP3A4 suggests POR may change
activities of CYP3A4 in patients (Flück et al., 2010; Nicolo et al.,
2010). There may be substrate specific effects of POR variants on
CYP3A4 activities. Agrawal et al. (2010) found that POR vari-
ants p.A287P and p.R457H had lower activity with all substrates.
The p.Q153R had 76–94% of WT activity with midazolam and
erythromycin, but showed 129–150% activity with testosterone
and quinidine (Agrawal et al., 2010). The polymorphism p.A503V
had 20–40% reduction in CYP3A4 activity with testosterone
and midazolam. With quinidine and erythromycin the p.A503V
has no significant change in activities (Agrawal et al., 2010).
Studies from us and others have reported normal CYP3A4 activ-
ity with POR p.G413S (Flück et al., 2010; Moutinho et al., 2012).
POR polymorphisms p.P228L, p.R316W, p.G413S, p.A503V, and
p.G504R have 40–100% activity in most assays (Table 3). The
p.A115V had less than 40–60% of activity, and p.V631I had
23–76% of wild-type activity (Huang et al., 2005).
Agrawal et al. (2008) found POR mutations p.A287P and
p.R457H resulted in almost complete loss of CYP1A2 and
CYP2C19 activities (Table 2). The polymorphism p.A503V had
85% of WT activity with CYP1A2 and 113% of WT activity with
CYP2C19 (Table 3). The p.Q153R, a disease-linked mutation
increased activity of CYP1A2 to 144% and CYP2C19 activity to
284% of WT.
In addition to CYP3A4 the CYP2D6 is another major drug
metabolizing enzyme (Zanger and Schwab, 2013). POR mutants
p.A287P and p.R457H have no CYP2D6 activity with synthetic
substrate EOMCC (Sandee et al., 2010). The p.A287P mutant
retained 25% of WT activity with dextromethorphan and bufu-
ralol as CYP2D6 substrates. The p.Q153R had increased activity
with CYP2D6. The p.A503V resulted in activities of 85% with
EOMCC, 62% with dextromethorphan, and 53% with bufuralol
(Sandee et al., 2010).
There may also be differences in effects of POR variants due
to presence of P450 isoforms but, this has not been explored in
detail. Subramanian et al. (2012) studied the polymorphic forms
of CYP2C9 (CYP2C9.1, CYP2C9.2, and CYP2C9.3) with POR
variants. POR variants p.A287P and p.R457H resulted in reduced
activities with all three variants of CYP2C9. The disease related
variant p.R153Q had higher activities with all variants of CYP2C9
(Subramanian et al., 2012).
POR VARIANTS IN DIFFERENT GENETIC POPULATIONS
A study on sequencing of POR gene in 842 healthy people
(Huang et al., 2008) detected 140 SNPs, and 43 of those were
in ≥1% of alleles. 32 variants were in protein coding regions, 2
in untranslated exon 1U, 94 in the introns and 12 in 5′ flank-
ing DNA. Among the 32 variations in protein coding region, 13
new variants resulted in amino acid change. The new variants
were p.delE53, p.P55L, p.D211N, p.G213E, p.P284L, p.P284T,
p.R406H, p.P452L, p.A462T, p.V472M, p.A485T, p.R600W, and
p.Y607C. The POR polymorphism p.A503V (rs1057868) (Huang
et al., 2005), was present in about 25% of all alleles (Huang
et al., 2008). Most of the polymorphic variants had >40% of WT
activities in different in vitro assays.
Some researchers have attempted to sequence POR gene in
human liver samples to study the impact of POR variant in enzy-
matic studies in liver microsomes. A study of POR sequence in
human liver samples by Xiao-Bo Zhong added 3 novel amino
acid variations (p.K49N, p.L420M, and p.L577P) (Hart et al.,
2008). The POR variant p.L577P had reduced activities in many
drug metabolizing P450 assays (Hart et al., 2008). Another study
of POR variation analysis by Ulli Zanger in 150 human liver
samples found 43 variations with 19 SNPs in exonic regions
(Gomes et al., 2009). They also found two combinatorial alleles of
(p.P228L+ p.A503V and p.A503V+ p.V631I) and similar to pre-
vious reports, the p.A503V allele was the most common variant
(Gomes et al., 2009).
Several new studies have sequenced POR gene in specific
population groups. Sequencing of POR gene in 235 Japanese
individuals (Saito et al., 2011) found 4 new amino acid changes
(p.T29M, p.R550W, p.R570C, and p.A659T). Here p.A503V was
present at a somewhat higher frequency of 0.434. A recent study
sequenced POR variants in distinct Jewish populations and iden-
tified 6 novel amino acid variants, p.S102P, p.V164M, p.V191M,
p.D344N, p.E398A, and p.D648N (Tomkova et al., 2012). The
average minor allele frequency (MAF) of p.A503V in differ-
ent reports have ranged from 0.25 to 0.45. Analysis of genomic
sequence data available at NCBI SNP database shows that there
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Table 3 | Influence of POR variants found in normal population on the enzyme activities of its redox partners.
POR DBSNP id CYP3A4 HO-1 Cyt NADPH Ox CYP17A1 CYP17A1 CYP19A1 CYP1A2 CYP2C19 CYP2D6
c red 17OH-ase 17,20 lyase
WT – 100 100 100 100 100 100 100 100 100 100
p.delE53 rs72553987 57 93 73 82 156 91
p.P55L rs72553988 67 123 82 115 114 83
p.A115V rs199634961 85 95 63 41 80 71 – – –
p.D211N rs72557914 27 59 57 62 52 52
p.G213E rs72557915 111 105 57 93 174 101
p.P228L rs17853284 101 106 75 72 100 41 – 20 39
p.P284T rs72557937 16 32 14 19 – –
p.P284L rs72557938 104 153 44 82 41 27
p.E300K rs11540674 93 104 112 146 85
p.R316W BV12016# 110 96 61 77 94 141 – 109 81
p.R406H rs72557929 62 78 61 57 125 155
p.G413S BV12020# 100 104 76 100 83 110 – 73 104
p.P452L rs72557935 16 12 48 61 21 83
p.A462T rs72557936 85 69 58 66 119 100
p.V472M rs72557946 23 24 58 46 54 77
p.A485T rs72557947 36 51 68 88 80 98
p.A503V rs1057868 107 97 67 56 68 58 – 85 113 85
p.G504R BV12031# 93 107 53 47 91 103 – 82 140 –
p.R600W rs72557950 67 56 38 40 36 60
p.Y607C rs72557954 – 20 76 40 7 24
p.V631I rs145782750 89 96 74 23 51 40 – 6 23
Activities are shown as percentage of the wild-type POR. POR, P450 oxidoreductase. Data were compiled from previous reports (Flück et al., 2004, 2010, 2011a;
Pandey et al., 2004, 2007, 2010; Huang et al., 2005, 2008; Agrawal et al., 2008, 2010; Nicolo et al., 2010; Sandee et al., 2010). # DBSNP id not available, these were
identified in a sequencing study by Bioventures Inc. (Solus et al., 2004) and are represented as Bioventure ID numbers BVxxxxx.
Enzymes/reactions and substrates (in parenthesis) listed in this table: CYP3A4: [BOMCC (7-Benzyloxy-4-trifluoromethylcoumarin)]; HO-1: Heme oxygenase-1 (heme);
Cyt c red: Cytochrome c reduction (cytochrome c); NADPH ox: NADPH oxidation (NADPH); CYP17A1 17OH-ase: (Progesterone); CYP17A1 17,20 Lyase: (17-hydroxy
Pregnenolone), CYP19A1: (androstenedione); CYP1A2,CYP2C19 and CYP2D6: [EOMCC (7-ethoxy-methyloxy-3-cyanocoumarin)].
FIGURE 6 | Impact of POR variants on CYP3A4 activity. A pie chart
showing the impact of POR variants on CYP3A4 activity. The variants which
had <5% of WT activity are grouped as red, variants with 5–25% of WT
activity are in orange, variants with 25–50% of activity are in yellow, and
variants with >50% activity are in green.
are some differences among different genetic groups (Figure 7).
In the Caucasian andHispanic populations the p.A503V allele fre-
quency is 31%, in Pacific Islanders 34%, and in Asian populations
the p.A503V allele is present at 38%. In the Japanese popula-
tion the p.A503V frequency is highest at 40% while the African
Americans group has the lowest presence at less than 15% of all
alleles. Homozygous presence of p.G5G (rs10262966, nucleotide
change GGA to GGG) silent mutation has been associated with
increased risk in African Americans (Haiman et al., 2007). This
variant is not present in European and Asian populations and
has a MAF of 0.023 in Hispanic population (Figure 8). In Sub-
Saharan Africans it is present in 30% of alleles (MAF 0.297) and
African Americans have the highest frequency with 40% of alle-
les (MAF 0.400) carrying the p.G5G variant of POR. The p.A50V
variant was also tested for association with increased breast can-
cer risk in same study but no linkage was observed (Haiman et al.,
2007).
IN VIVO DRUG CLEARANCE STUDIES EXAMINING THE
IMPACT OF POR VARIANTS
Several studies have now examined the role of POR variants
on in vivo drug clearance using many different standard drugs
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FIGURE 7 | Allele frequencies of POR variant A503V in different
population groups. The p.A503V variant of POR (rs1057868) is most
common across all population groups. In various sequencing studies
specifically targeting POR gene as well as large scale sequencing projects
the POR p.A503V is present as most common minor allele. The average
minor allele frequency in different studies ranges from 0.25 to 0.45. A closer
look at the data revealed some differences. In the Caucasian and Hispanic
populations the p.A503V allele is present in 31% of alleles, while in Pacific
Islanders (34%) and Asian populations (38%) there is a slight but consistent
increase. In the Japanese population the p.A503V frequency is highest (40%)
while in African Americans it is present in less than 15% of all alleles. Alleles
with p.503A are in green while p.503V is in orange. Data were compiled from
information available in NCBI SNP database as of April 2014
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1057868).
as markers. One report has described in vivo drug metabolism
activities in a POR p.A287P homozygous patient and her het-
erozygous mother (Tomalik-Scharte et al., 2010). Genotyping of
P450 enzymes predicted normal to high P450 activities in both
the patient and her mother. The in vivo results showed subnor-
mal activities of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 in
the patient. The heterozygous mother had reduced CYP1A2 and
CYP2C9 activities. These data are in agreement with disruption of
in vitro CYP3A4 activities by p.A287P variant of POR reported by
us (Flück et al., 2010; Nicolo et al., 2010). In patients with PORD,
the in vitro and in vivo activities of POR dependent P450 may be
taken into account to modify drug dosages and supplementation
with steroids.
POR variant p.A503V (POR∗28) had higher levels of CYP3A
activities based on midazolam clearance (Oneda et al., 2009).
Yang et al have studied the effect of POR variant p.A503V on
in vivo CYP3A activity in healthy Chinese men (Yang et al., 2011).
Out of 73 subjects (CC 21, TT11; CT 41) the midazolam metabo-
lite ratio was greater in the TT group compared with carriers
of the C allele. The p.A503V variant of POR had increased 1-
hydroxylation of midazolam. Further analysis showed association
with hepatic but not intestinal CYP3A activities (Yang et al.,
2011). There was no significant differences in combined hepatic
plus intestinal CYP3A activity.
A study tested the impact of POR p.A503V on metabolism
of tacrolimus (de Jonge et al., 2011). They found lower levels
of tacrolimus in carriers of p.A503V allele but in the individ-
uals with CYP3A5∗3/∗3 allele, the p.A503V POR had no effect
(de Jonge et al., 2011). Another study measured the impact of
p.A503V (rs1057868, DNA change GCC to GTC) allele of POR on
metabolism of tacrolimus in healthy Chinese men (Zhang et al.,
2013). There was no difference in tacrolimusmetabolism between
two POR alleles. Further analysis showed no significant differ-
ences in tacrolimus pharmacokinetics in CYP3A5 non-expressers
(CYP3A5∗3/∗3). The mean tacrolimus exposure for the p.A503V
CC homozygotes in CYP3A5 expressers (CYP3A5∗1/∗1 or ∗1/∗3)
were much higher than the p.A503V CT heterozygotes. These
studies suggest a role for p.A503V allele of POR in the variability
of tacrolimus exposure levels. In vitro studies of CYP3A5 activities
comparing normal and p.A503V variants of POR may confirm
this hypothesis.
A CYP1A2 genotyping study in smokers also checked
POR polymorphic variants for potential linkage to metabolic
defects (Dobrinas et al., 2012). During smoking there was
no impact of any POR polymorphisms on CYP1A2 activ-
ity. CYP1A2 activity increased after smoking cessation in POR
rs2302429A and rs1057868T (p.A503V) carriers. The carri-
ers of POR rs2286823A and of rs17148944G-rs10239977C-
rs3815455C-rs2286823A-rs2302429G-rs1057868C (503A) had
decreased CYP1A2 activity.
CONCLUSIONS
PORD is more complex than any single enzyme or protein defi-
ciency (Janner et al., 2006; Flück et al., 2011c; Camats et al., 2012).
It affects drug and xenobiotic metabolism pathways (Henderson
et al., 2006; Flück et al., 2010; Nicolo et al., 2010). Variants of
POR have different interactions with different redox partners.
Effect of POR variants on drug metabolizing P450 enzymes needs
detailed studies. Deposition of heme in liver lowers cytochrome
P450 levels and enzymatic activities (Pandey et al., 1995, 1996).
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FIGURE 8 | Allele frequencies of POR variant G5G associated with
increased breast cancer risk. The p.G5G variant of POR (rs10262966) is
associated with increased risk of breast cancer when present in
homozygous form in African Americans (Haiman et al., 2007). Genomic
data from various sequencing projects show a clear pattern for the
presence of rs10262966 in different populations. In the Caucasian and
Asian populations rs10262966 is not present, while in Hispanic population it
is present with a minor allele frequency of 0.023. In the Sub-Saharan
African population the rs10262966 frequency is higher at 0.297 while in
African Americans it is present in 40% of all alleles. Data were compiled
from information available in NCBI SNP database as of April 2014
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=10262966).
POR variants with lower activities may complicate these symp-
toms and result in a more severe disease. Heme oxygenase plays a
major role in limiting the severity of malaria and sepsis infections
(Pamplona et al., 2007; Larsen et al., 2010; Pandey et al., 2010;
Ferreira et al., 2011). There may be potential links between the
common POR variants and pathogenesis of infections. External
flavin supplementation reverts loss of activity of some POR vari-
ants (Nicolo et al., 2010). An interesting possibility to explore in
future experiments is whether external FMN can receive electrons
from boundNADPH in POR as reported for a B. subtilis reductase
(Deller et al., 2006). Whether flavin treatment may help patients
with POR deficiency remains untested in clinical settings.
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